Lexeo Therapeutics releases corporate presentation outlining cardiac gene therapy pipeline, AAVrh.10 platform
LXEO•LX2020 update and next steps
LX2020 for PKP2 arrhythmogenic cardiomyopathy: high-dose data update expected in Q4 2026; regulatory engagement planned in 2026.
LX2006 development update for Friedreich ataxia cardiomyopathy
LX2006 for Friedreich ataxia cardiomyopathy: pivotal SUNRISE-FA 2 initiated; topline data expected in 2H 2027; BLA filing targeted 1H 2028.
SUNRISE-FA 2: 26 participants; one-time 1.2x10^12 vg/kg IV dose; primary endpoint LVMi by cardiac MRI at 6 months.
Phase I/II LX2006 data: mean LVMi fell 18% at 6 months in patients with abnormal baseline LVMi; cohorts 2-3 showed 28% reduction.
Corporate presentation highlights cardiac gene therapy platform
Lexeo Therapeutics released a corporate presentation outlining its cardiac gene therapy pipeline and AAVrh.10 platform.
Lexeo highlighted a cardiac gene therapy platform built on its AAVrh.10 capsid, citing 27 patients treated across two clinical programs.
